NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing intranasal and intramuscular vaccines, based on its patented NanoStat™ technology platform. Founded in 2000 as a spin-out from the Center for Biologic Nanotechnology at the University of Michigan, NanoBio’s lead product candidates include vaccines for RSV, seasonal and pandemic influenza, pertussis, anthrax and HSV2. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease

Research Grants show all

NIH5

Publications show all

Nanobio has published 195 articles.

Patents show all

32Applications9Issued

Clinical Trials show all

3Phase 32Phase 12Phase 2

SEC Filings show all

D4

Private Funding Events

DateOfferedSoldType
2009-05-29Indefinite$10,000,000Other
2008-12-11UnknownUnknownOther (Paper Filing)

Key Executives

  • James R. Baker, Jr.
    Executive Officer
  • David Peralta
    Executive Officer
  • Norman C. Selby
    Director
  • Ronald M. Cresswell
    Director
  • Daniel B. Dubin
    Director
  • Robert C. Moellering
    Director
  • David M. Stout
    Director